Uveal Neoplasms Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The uveal neoplasms market was valued at USD 1.23 Billion in 2025. It is poised to grow at a CAGR of 5.36% during the forecast period of 2026-2035, and reach USD 2.07 Billion by 2035. The market growth is driven by the by a combination of epidemiological expansion, therapeutic innovation, and structural healthcare shifts.

Key Market Trends and Insights

• Based on treatment type, the therapy segment is likely to lead the market in the forecast period.
• By route of administration, the injectable segment is expected to dominate the market in the forecast period.
• The hospital pharmacies segment is expected to witness significant market share throughout the historical period.

Market Size and Forecast

• Market Size (2025): USD 1.23 Billion
• Projected Market Size (2035): USD 2.07 Billion
• CAGR (2026-2035): 5.36%

Uveal Neoplasms Market Overview

A uveal neoplasm is a tumor arising from melanocytes within the uveal tract of the eye, comprising the iris, ciliary body, and choroid. Uveal melanoma is the dominant subtype and represents the most common primary intraocular malignancy in adults. The market was valued at USD 1.23 Billion in 2025. The growth in the market is driven by the rising metastatic burden, expanding HLA-targeted T-cell receptor therapies, and the growing role of proton therapy and plaque brachytherapy in eye-sparing care.

Uveal Neoplasms Market Growth Drivers

Rising Advancements in Targeted Immunotherapies to Support the Market Expansion

The increasing development and commercialization of targeted immunotherapies are significantly driving growth in the market. The growing focus on precision-based biologics, T-cell engager technologies, and long-term survival benefits is encouraging pharmaceutical companies to expand research investments and accelerate innovation in rare disease therapeutics. For instance, in April 2026, Immunocore Holdings plc announced that KIMMTRAK® demonstrated a substantial five-year overall survival benefit in metastatic uveal melanoma patients during the American Association for Cancer Research 2026 meeting. The strong clinical outcomes and durability of advanced immunomodulating therapies are reinforcing confidence in next-generation rare disease treatments, thereby supporting therapeutic advancements and overall market growth

Uveal Neoplasms Market Trends

Some of the notable trends shaping the market include targeted therapy advancements and precision oncology integration.

Precision Oncology Advancements are Likely to Boost Therapeutic Market Growth

The increasing focus on precision oncology and biomarker-driven therapies is emerging as a significant trend in the hereditary angioedema therapeutic market, as pharmaceutical companies continue to invest in advanced targeted treatment development. For instance, in April 2026, IDEAYA Biosciences and Servier announced positive topline Phase 2/3 trial results for darovasertib combined with crizotinib, demonstrating statistically significant progression-free survival improvement and higher response rates in metastatic uveal melanoma patients. This development reflects the broader industry trend toward innovative targeted therapies with enhanced efficacy and personalized treatment approaches, which is expected to strengthen therapeutic innovation and accelerate overall market growth.

Uveal Neoplasms Market Segmentation

Market Breakup by Treatment Type

• Drugs
• Rituximab
• Ibritumomab
• Imatinib
• Sorafenib
• Others
• Therapy
• Transpupillary Thermotherapy
• Radiation Therapies
• Proton Therapy
• Others

Market Breakup by Route of Administration

• Oral
• Injectable
• Others

Market Breakup by Distribution Channel

• Hospitals Pharmacies
• Online Pharmacies
• Retail Pharmacies

Market Breakup by Region

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Uveal Neoplasms Market Share

Therapy Segment Expected to Lead the Market Segmentation by Treatment Type

The therapy segment is expected to lead the market due to the growing focus on targeted biologics, improved relapse prevention strategies, and increasing clinical advancements in rare immune-related disorders. For instance, in December 2024, the European Organisation for Research and Treatment of Cancer and Immunocore announced the enrollment of the first patient in the Phase 3 ATOM trial evaluating tebentafusp for relapse prevention in high-risk uveal melanoma patients. The study highlights rising investment in innovative drug-based therapeutics, supporting stronger treatment adoption and continued market growth potential.

Uveal Neoplasms Market Analysis by Region

Among all the regions, United States is likely to lead the market, supported by elevated diagnosis rates among Caucasian populations and a robust ocular oncology infrastructure. According to the National Cancer Institute, around 1,700 patients are diagnosed with uveal melanoma annually in the United States. The country also benefits from significant investments in research and development activities and favorable access to innovative biologic therapies. In addition, increasing diagnosis rates and supportive healthcare policies are contributing to market growth, further strengthening the country’s leading position in the market.

Leading Players in the Uveal Neoplasms Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Merck & Co., Inc

Merck & Co., Inc biopharmaceutical company engaged in oncology research and immunotherapy development. Its anti-PD-1 therapy, KEYTRUDA, is being evaluated across multiple cancer indications, including advanced and metastatic tumors. Through ongoing clinical trials and expanding immuno-oncology programs, the company contributes to innovation in treatments associated with rare and aggressive ocular cancers, supporting advancements in the therapeutic landscape.

F. Hoffmann-La Roche Ltd

Roche contributes in the uveal neoplasm market through Tecentriq trials in advanced melanoma and supportive diagnostic platforms via its Ventana and Foundation Medicine units. In 2024, Roche expanded next-generation sequencing collaborations to refine HLA typing and BAP1 mutation screening, enabling more accurate patient stratification for targeted uveal neoplasm therapeutics across major markets.

Pfizer Inc.

Pfizer pursues uveal melanoma through MEK and PKC inhibitor pipeline assets and biosimilar oncology platforms. Following its 2023 Seagen acquisition, the company is integrating antibody-drug conjugate technology into rare ocular oncology programs. Its 2024 cost-realignment plan accelerates investment toward high-margin precision therapies relevant.

Bristol-Myers Squibb Company

Bristol-Myers Squibb is a biopharmaceutical company focused on developing innovative therapies across oncology, immunology, cardiovascular, and other therapeutic areas. The company’s immunotherapy products, including Opdivo and Yervoy, have demonstrated significant advancements in cancer treatment through multiple clinical studies. Bristol Myers Squibb continues to strengthen its position in the oncology market by expanding immune-oncology research, which is also contributing to growing interest in immunotherapeutic approaches for uveal neoplasms and other rare cancers.

Other key players in the market are Bayer AG, Spectrum Pharmaceuticals Inc., Amgen Inc., Eli Lilly & Co., AstraZeneca plc., and Novartis AG.

Key Questions Answered in the Uveal Neoplasms Market Report

• What was the uveal neoplasms market value in 2025?
• What is the uveal neoplasms market forecast outlook for 2026-2035?
• What major factors aid the demand for the uveal neoplasms market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major uveal neoplasms market trends?
• Which treatment type is expected to dominate the market segment?
• Which route of administration is projected to lead the market segment?
• Which distribution channel is anticipated to drive the market segment?
• Who are the key players in the uveal neoplasms market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?